Properties (100)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Loxo_Oncology
gptkb:Avid_Radiopharmaceuticals ImClone Systems |
| gptkbp:approves |
numerous drugs approved
|
| gptkbp:awards |
Best Places to Work
Top Employer Fortune 500 company DiversityInc Top 50 |
| gptkbp:CEO |
gptkb:David_A._Ricks
|
| gptkbp:clinicalTrials |
conducts numerous clinical trials annually
collaborations with universities partnerships with hospitals over 100 ongoing investments in biotechnology |
| gptkbp:community_involvement |
supports local charities
provides scholarships supports STEM education engages in volunteer work promotes health education |
| gptkbp:employees |
over 35,000
|
| gptkbp:focus |
mental health
neurodegenerative diseases rare diseases autoimmune diseases cancer treatment cardiovascular health infectious diseases pain management diabetes care |
| gptkbp:founded |
1876
|
| gptkbp:founder |
gptkb:Eli_Lilly
|
| gptkbp:global_presence |
over 120 countries
|
| gptkbp:headquarters |
gptkb:Indianapolis,_Indiana
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lilly USA
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
$200 billion (2021)
|
| gptkbp:marketedAs |
gptkb:Tremfya
gptkb:Basaglar gptkb:Lantus gptkb:Tysabri gptkb:Strattera Cymbalta Humalog Zyprexa Breztri Aerosphere Trulicity Cialis Zyban Emgality Olumiant Taltz Verzenio Forteo Alimta Cyramza Verapamil ReoPro Retevmo Xigris |
| gptkbp:partnerships |
gptkb:Eli_Lilly_and_Company_Foundation
gptkb:Boehringer_Ingelheim gptkb:Pfizer |
| gptkbp:patentCitation |
over 10,000 active patents
|
| gptkbp:philanthropy |
gptkb:Lilly_Foundation
|
| gptkbp:products |
insulin
antidepressants oncology drugs |
| gptkbp:research |
neurodegenerative diseases
cancer treatments collaborates with academic institutions invests heavily in R&D Daniel Skovronsky diabetes treatments focuses on innovative therapies develops biologics develops cell therapies develops gene therapies develops small molecules develops vaccines |
| gptkbp:research_areas |
autoimmune diseases
cardiovascular diseases pain management |
| gptkbp:revenue |
$24.5 billion (2020)
$24 billion (2022) |
| gptkbp:stockExchange |
gptkb:LLY
|
| gptkbp:subsidiary |
gptkb:Lilly_France
gptkb:Lilly_Japan gptkb:Lilly_Research_Laboratories gptkb:Lilly_Canada Lilly USA, LLC |
| gptkbp:sustainability_initiatives |
community engagement
diversity and inclusion ethical sourcing employee well-being global health initiatives clinical trial transparency environmental responsibility access to medicines |
| gptkbp:website |
www.lilly.com
|